Healthcare Industry News: vascular access
News Release - May 11, 2012
RyMed Technologies Wins Patent Infringement CaseFederal Jury Rules Unanimously for RyMed, against ICU Medical
FRANKLIN, Tenn.--(Healthcare Sales & Marketing Network)--A federal jury has found in favor of RyMed Technologies and against ICU Medical (Nasdaq: ICUI) in a closely-watched patent infringement case. The jury ruled that RyMed’s InVision-Plus® with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.
The unanimous ruling by an eight-person jury means that ICU Medical can no longer make any claim that RyMed’s products literally infringe on an in-force ICU Medical patent, said Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed Technologies.
“This is a major victory for RyMed,” Ryan said. “The jury’s decision proves that our claims about this case have been correct. It reinforces our ability to continue providing all of RyMed’s innovative technology to the market. In addition to providing a significant boost to our future business prospects, it also affirms our ongoing efforts to bring clinicians and patients the very best in IV catheter safety technology.”
The jury decision was announced Wednesday, May 9th in a case heard before Judge Leonard P. Stark, in the United States District Court for the District of Delaware. The patent in question was U.S. Patent Number 5,685,866. The case was ICU Medical Inc. v. RyMed Technologies Inc., case number 1:07-cv-00468.
About RyMed Technologies, Inc.
Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company’s products are designed to help reduce catheter occlusion, catheter-related infections, and biofilm development commonly associated with vascular access devices. More than 10 years of research and development have gone into the InVision-Plus product line. Numerous studies regarding the efficacy of the InVision-Plus Needleless IV Connector have been published in the last six years—which is particularly important in light of the growing incidence of central line associated bloodstream infections (CLABSI).
For more information on the product and published studies, access www.rymedtech.com or call (615) 790-8093. The company is headquartered in Franklin, Tenn.
Source: RyMed Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.